Display options
Cite
Ji F, Ma D, Liu Z, et al. Rosiglitazone amplifies the sensitivity of docetaxel and reduces the expression of CD44v6. Oncol Lett. 2014;7(4):1284-1288doi: 10.3892/ol.2014.1824.
Ji, F., Ma, D., Liu, Z., & Xie, X. (2014). Rosiglitazone amplifies the sensitivity of docetaxel and reduces the expression of CD44v6. Oncology letters, 7(4), 1284-1288. https://doi.org/10.3892/ol.2014.1824
Ji, Fahe, et al. "Rosiglitazone amplifies the sensitivity of docetaxel and reduces the expression of CD44v6." Oncology letters vol. 7,4 (2014): 1284-1288. doi: https://doi.org/10.3892/ol.2014.1824
Ji F, Ma D, Liu Z, Xie X. Rosiglitazone amplifies the sensitivity of docetaxel and reduces the expression of CD44v6. Oncol Lett. 2014 Apr;7(4):1284-1288. doi: 10.3892/ol.2014.1824. Epub 2014 Jan 24. PMID: 24944709; PMCID: PMC3961430.
Copy Download .nbib Format: NLM
Share it on

Oncol Lett. 2014 Apr;7(4):1284-1288. doi: 10.3892/ol.2014.1824. Epub 2014 Jan 24.

Rosiglitazone amplifies the sensitivity of docetaxel and reduces the expression of CD44v6.

Oncology letters

Fahe Ji, Dongchu Ma, Zhaozhe Liu, Xiaodong Xie

Affiliations

  1. Department of Oncology, The General Hospital of Shenyang Military Command, Shenyang, Liaoning 110840, P.R. China.

PMID: 24944709 PMCID: PMC3961430 DOI: 10.3892/ol.2014.1824

Abstract

Breast cancer seriously impairs physical and mental health in females. Currently, with further investigation into drugs, a number of new pharmacological effects have been found that offer new methods for clinical application in the treatment of breast cancer. As a widely used antidiabetic drug, rosiglitazone (Ros) has become well known for its anticancer effects, mediated by the activation of peroxisome proliferator-activated receptor γ and downregulated expression of the associated invasion gene. The objective of the present study was to investigate the combination of Ros and docetaxel (DOC) and whether DOC has any effect on breast cancer cell lines. The results showed that the combination of Ros and DOC may cooperate to increase anti-growth efficacy. The additive inhibitory effects on cell proliferation were sequence-dependent and are not likely to be associated with cell cycle arrest. This suggested that the target activation of associated factors of the signaling pathway by Ros may be a compelling ally in cancer treatment. In addition, evidence was provided for a convergence of Ros and DOC to induce the reduced expression of CD44v6. Future studies are required to confirm which associated gene of Ros is significant in blocking the signaling pathway.

Keywords: CD44v6; cell cycle; cell proliferation; docetaxel; rosiglitazone

References

  1. Oncology. 2010;79(3-4):204-10 - PubMed
  2. Eur J Pharmacol. 2008 Sep 4;591(1-3):43-51 - PubMed
  3. Malays J Pathol. 2006 Dec;28(2):83-6 - PubMed
  4. Cancer Biol Ther. 2007 Jan;6(1):99-106 - PubMed
  5. Int J Hematol. 2007 Apr;85(3):231-7 - PubMed
  6. Gut. 2004 Mar;53(3):331-8 - PubMed
  7. Cell Cycle. 2006 Jul;5(14):1523-7 - PubMed
  8. World J Gastroenterol. 2009 Jan 28;15(4):441-8 - PubMed
  9. BMC Cancer. 2009 Apr 08;9:107 - PubMed
  10. Anticancer Res. 2010 Oct;30(10):4237-43 - PubMed
  11. Curr Med Chem. 2007;14(19):2009-23 - PubMed
  12. Dig Dis Sci. 2003 Oct;48(10):2005-17 - PubMed
  13. Int J Clin Oncol. 2002 Aug;7(4):254-64 - PubMed
  14. Carcinogenesis. 2007 Jul;28(7):1379-86 - PubMed
  15. Sheng Wu Gong Cheng Xue Bao. 2013 Feb;29(2):153-60 - PubMed
  16. Br J Cancer. 2010 Oct 26;103(9):1343-8 - PubMed
  17. Biochem J. 2007 Aug 1;405(3):439-44 - PubMed
  18. Dig Dis Sci. 2007 Sep;52(9):2305-11 - PubMed
  19. Ai Zheng. 2006 Aug;25(8):960-6 - PubMed
  20. Ai Zheng. 2006 Oct;25(10):1291-5 - PubMed

Publication Types